((自动化翻译由路透提供，请见免责声明 ))
11月11日 - ** 药物开发商 Rapt Therapeutics 股价下跌 42.4% 至 1.66 美元
** 该公司称，根据美国食品及药物管理局（FDA）最近的反馈，它已停止开发治疗湿疹和哮喘的药物Zelnecirnon。
** 在作出这一决定之前，美国食品及药物管理局在 2 月份对该药物的临床试验进行了搁置，原因是一名患者出现了严重的肝损伤病例。
** 公司表示将在 2025 年上半年确定一种新的实验疗法。
** 包括盘中走势在内，股价下跌 93.4
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.